Evaluation agreements have been the cornerstone of technology licensing from the outset. This report focuses on option and valuation agreements and clauses as part of broader agreements between Big Pharma-Big Pharma, Big Pharma – small business and small business – and provides a detailed overview of all these transactions. An option contract differs in that the option is often an integral part of an agreement already reached by the parties that gives the party the right of option to maintain or extend certain rights to the already connected technology. Dublin, April 06, 2020 (GLOBE NEWSWIRE) — The report “Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020” has been added to the ResearchAndMarkets.com. This report provides details on recent option and valuation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. The fully revised and updated report provides details on the option and evaluation agreements from 2014 to 2020. There are two main forms of commercial terms that allow a party to a transaction to secure rights in an asset subject to a future event, namely option and valuation. Assessment agreements allow a party to the company to acquire rights to an active technology or ingredient, subject to a period of time to assess the quality, scope and applicability of the technology at its intended point of application. Typically, the technology is at an early stage and/or is not proven, and the partner company wants to evaluate the technology as part of the due diligence process before signing a long-term licensing agreement. An option contract differs in that the option is often an integral part of an agreement already reached by the parties that gives the party the right of option to maintain or extend certain rights to the already connected technology. Option agreements are becoming increasingly popular because they create additional flexibility in an agreement for additional rights that the parties do not want to establish at the beginning of the agreement. This report focuses on option and valuation agreements and clauses as part of broader agreements between Big Pharma-Big Pharma, Big Pharma – small business and small business – and provides a detailed overview of all these transactions.
The report provides a detailed understanding and analysis of how and why companies enter into valuation options and transactions. The majority of transactions are multi-component, with the licensor retaining either an option or an evaluation right to the product resulting from the research cooperation. There are also many pure option and evaluation offerings where the product manufacturer acquires a partner to advance the product or connection to a point where the licensee could apply for a licensing agreement. Understanding the flexibility of a potential partner`s negotiated terms provides crucial insight into the negotiation process in terms of what you can expect when negotiating the terms. While many small businesses will be looking for details about payment clauses, the devil is in the details when it comes to how payments are triggered – contract documents give that insight where press releases and databases don`t. This report contains a complete list of all option and valuation transactions announced since 2014 that are listed in the database of current agreements and alliances, including financial terms, if any, as well as links to online copies of option agreement and valuation documents submitted by the companies and their partners to the Securities Exchange Commission. Contract documents provide the answers to many questions about a potential partner`s flexibility on a variety of important issues, many of which will have a significant impact on each party`s ability to extract value from the business. Key Benefits Analysis of the Structure of Option and Valuation Agreements with Many Real Case Studies Evaluation agreements allow a party to the company to acquire rights to an active technology or ingredient, subject to a period of time to assess the quality, scope and applicability of the technology at the intended endpoint. Typically, the technology is at an early stage and/or is not proven and the partner company wishes to evaluate the technology as part of the due diligence process before signing a long-term licensing agreement.
This report provides details on recent option and valuation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. The fully revised and updated report provides details on the option and assessment agreements from 2014 to 2021. The Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides full access to available records for more than 1,000 option and valuation transactions, including contract documents, if applicable. 2.5.2. Reasons for including co-promotion options in a transaction Chapter 2 – Trends in the closing of option and valuation transactions There are two main forms of trading terms that allow a party to a transaction to guarantee rights in an asset subject to a future event, namely option and valuation. Main topics covered: 1. Introduction2. Trends in options and transaction valuation2.1. Introduction2.2. Difference between option and evaluation offers2.2.1. Types of option agreements2.3.
Trends in option and valuation offerings since 20142.3.1. Options and valuation Transactions by year since 20142.3.2. Options and evaluation Transactions after development phase since 20142.3.3. Options and valuation Transactions by sector since 20142.3.4. Options and evaluation Therapeutic area transactions since 20142.3.5. Options and valuation Trading by type of technology since 20142.3.6. Options and valuation Transactions by the most active company since 20142.4. Options-based transactions2.4.1.
Attributes of options-based transactions2.4.2. Reasons for closing an options-based transaction2.4.3. Use of options exercise2.4.4.The future of options-based trading2.5. Co-promotion options2.5.1. Co-promotion attributes for multi-component offerings2.5.2. Reasons for including co-promotion options in a business2.5.3. Exercise of the right to participate2.5.4. Participation rights as a currency of exchange2.5.5.
The future of co-promotion in multi-component agreements2.6. Options for acquiring companies2.6.1. Case Study 1: Cephalon – Ception2.6.2. Case Study 2: Endo – Indevus2.6.3. The future of the Deal3 acquisition option. Overview of the structure of the option and evaluation operation 3.1. Introduction3.2. Structure of the option and valuation agreement3.2.
Examples of evaluation agreements3.2.1.a. Case Study 3: Idenix Pharmaceuticals – Janssen Pharmaceuticals3.3. Structure of option agreements3.3.1. Examples of option agreements3.3.1.a. Licensing OptionCase Study 4: Biogen Idec – Isis Pharmaceuticals3.3.1.b. Application Extension Option/TerritoryCase Study 5: Novartis -Prometheus3.3.1.c. Funding OpportunityCase Study 6: Amarantus BioSciences – Power3 Medical Products3.3.1.d. Acquisition OptionCase Study 7: Teva – OncoGenex Pharmaceuticals3.3.1.e. Possibility of manufacture/deliveryCase study 8: NPS Allelix – Nycomed3.4. Possibility of acquiring the structure of the contract3.4.1. Example of call option clauses3.4.1.a.
Case Study 9: ViroPharma- Meritage Pharma3.4.1.b. Case Study 10: Nuvasive – Progentix Orthobiology4. Main options and valuation transactions4.1. Introduction4.2. Key value valuation options and offers5. Top 25 Most Active Options and Valuation Traders5.1. Introduction5.2. Top 25 most active options and valuation traders6.
Directory 6.1 Option and Evaluation Contracts. Introduction6.2. Option and valuation transactions with contracts since 2014 Companies mentioned An overview of the terms contained in an option and valuation agreement as well as examples of clauses in practice Option agreements are becoming increasingly popular as they create additional flexibility within a transaction for additional rights that the parties do not want to bind at the beginning of the agreement. Full access to more than 1,200 real options and valuation transactions concluded by the world`s biopharmaceutical companies An in-depth understanding of options and valuation trends since 2014 2.2. Difference between option and evaluation offers 5.2. Top 25 Most Active Options and Valuation Traders Email address cannot be subscribed. Please try again… Learn more about FindLaw`s newsletters, including our Terms of Service and Privacy Policy. 3.2.1.a.
Case Study 3: Idenix Pharmaceuticals – Janssen Pharmaceuticals 3.4.1.b. Case Study 10: Nuvasive – Progentix Orthobiology. . Understand the key transaction terms that companies have agreed to in previous agreements ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com. This website is protected by reCAPTCHA and Google`s privacy policy and terms of use apply. . Case Study 6: Amarantus BioSciences – Power3 Medical Products. Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 offers the reader the following key benefits: For more information on this report, see www.researchandmarkets.com/r/rjk94j. Chapter 6 – List of option and valuation contracts 2.5.1. Co-promotion attributes for multi-component transactions.
The report “Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021” has been added to l.com researchAndMarkets offering. . Save my name, email address, and website in this browser for the next time I comment. 6.2. Option and valuation transactions with contracts since 2014 Your email address will not be published. Required fields are marked * Research and Markets also offers custom search services that provide targeted, comprehensive, and personalized searches. .